西罗莫司片肝移植患者可以用吗？

Can sirolimus tablets be used by liver transplant patients? The safety and effectiveness of rapamycin (sirolimus) as an immunosuppressant in liver transplant or lung transplant patients have not yet been determined. Patients are recommended to use the drug under the guidance of a doctor.

Rapamin (sirolimus tablets) was originally used as a low-toxicity antifungal agent and immunosuppressant. In 1989, RAPA was tested as a new drug for organ transplant rejection. Based on animal experiments and the impact of clinical application, it is an effective and good new immunosuppressant with low toxicity and no nephrotoxicity.

Rapamin () is mainly used clinically to prevent organ rejection in patients aged 13 or above who have received kidney transplants. Recommended usage is oral administration, once daily. After transplantation, patients should start taking it as soon as possible. For de novo kidney transplant recipients, sirolimus is recommended in combination with cyclosporine and corticosteroids. A loading dose of sirolimus should be taken for the first time, which is 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. To maintain sirolimus plasma concentrations within the target range, sirolimus plasma concentrations should be monitored. Dose Adjustment: In patients 13 years of age and older but weighing 40 kg or less, the starting dose should be adjusted to 1 mg/m 2 /day based on body surface area. The loading dose should be adjusted to 3 mg/m 2 . It is recommended that the maintenance dose of sirolimus be reduced by approximately 1/3 to 1/2 in patients with hepatic impairment. The loading dose of sirolimus does not need to be adjusted. In patients with hepatic impairment, monitoring of sirolimus trough concentrations is recommended. No dose adjustment is required due to renal impairment.

Recommended related hot articles: /newsDetail/83748.html